Biology of Blood and Marrow Transplantation · 2008 · 116 citations · 16 references
MedicineOncologyPharmacotherapyChemotherapyImmunotherapyStem Cell TransplantationCancer Stem CellsChemotherapy In Hematologic MalignanciesHematopoietic Stem Cell TransplantationMultiple MyelomaMyelosuppression ManagementStem Cell MobilizationG-csf TherapyGranulocyte Colony-stimulating Factor MobilizationGranulocyte-macrophage Colony-stimulating Factor MobilizationLenalidomide TherapyMobilization In Multiple MyelomaMultiple Myeloma TherapyMultiple Myeloma TreatmentStem Cell Harvesting
A total of 28 treatment-naïve patients with stage II or III multiple myeloma (MM) were treated with the combination of clarithromycin, lenalidomide, and dexamethasone (BiRD). Stem cells were collected following granulocyte-colony stimulating factor (G-CSF) or cyclophosphamide (Cy) plus G-CSF mobilization at maximum response. Sufficient stem cells for 2 autologous stem cell transplants were collected from all patients mobilized with Cy plus G-CSF, versus 33% mobilized with G-CSF alone (P < .0001). The duration of prior lenalidomide therapy did not correlate with success of stem cell harvests (P = .91). In conclusion, Cy can be added to G-CSF for stem cell mobilization to successfully overcome the suppressive effect of prior treatment with lenalidomide.
16
International uniform response criteria for multiple myeloma
Brian G.M. Durie, J-L Harousseau, Jesús F. San Miguel et al. · Leukemia · 2006 · 2.6K citations
Medicine, Hematology, Oncology +12
M Ichel A Ttal, J Ean, A.A. D uuml nne et al. · 2013 · 2.2K citations
Medicine, Hematology, Oncology +14
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Donna M. Weber, Christine Chen, Rubén Niesvizky et al. · New England Journal of Medicine · 2007 · 1.2K citations · Full text